bioc20161227_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549  

FORM 8-K  

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

 

December 29, 2016 

BioCardia, Inc.

(Exact name of Registrant as specified in its charter)  

  

Delaware

 

0-21419

 

23-2753988

(State or other jurisdiction of

incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

125 Shoreway Road, Suite B
San Carlos, California 94070

(Address of principal executive offices, including zip code)

 

 

(650) 226-0120

(Registrant’s telephone number, including area code)

 

 

N/A
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

  

 
 
 

 

  

ITEM 8.01     Other Events.

 

On December 29, 2016, BioCardia, Inc. (the “Company”) issued a press release announcing the initiation of the Company’s pivotal CardiAMP heart failure trial at two U.S. centers.

 

A copy of the press release containing the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

 

ITEM 9.01.    Financial Statements and Exhibits.

 

(d) Exhibits

 

A list of exhibits furnished as part of this report is set forth in the Exhibit Index, which is presented elsewhere in this document, and is incorporated herein by reference.

 

 
 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

BIOCARDIA, INC.

Date: December 29, 2016

 

 

By: /s/ Peter Altman_____________

 

 

Peter Altman

 

President and CEO

  

 
 
 

 

EXHIBIT INDEX

 

     

Exhibit No.

  

Exhibit Description

   

  99.1

  

Press Release dated December 29, 2016